New COVID-19 Antigen Test Gets FDA Emergency Use Authorization
There’s a new rapid COVID-19 test on the market that uses the same technology found in your Wi-Fi router
From the LifeMinute.TV Team
July 29, 2021
Qorvo Biotechnologies, a semiconductor company that delivers radio frequency solutions that connect our smart devices, has just received FDA emergency use authorization for COVID-19 antigen testing through its new Omnia platform. The diagnostic tool uses high frequency, bulk acoustic wave sensors – technology that can be found in your home Wi-Fi networks – to detect COVID-19 antigens, providing accurate results in approximately 20 minutes.
Omnia represents a paradigm shift in how diagnostic testing is done. Instead of relying on traditional molecular testing methods, it uses RF sensors to detect concentrations within a sample. Qorvo’s goal is to provide lab equivalent results. We believe this platform has the potential to give physicians fast access to test data they can trust.
To help advance the production of the Omnia diagnostic test platform, Qorvo Biotechnologies has been awarded a $24.4 million contract from the National Institutes of Health to help meet the clinical need for rapid antigen testing.
Along with the FDA’s emergency use authorization, the recent NIH contract is recognition that the Omnia platform can help address the public health need for rapid, accurate, and clinically reliable diagnostic testing.
For more information, visit qorvobiotech.com.